Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Karyopharm Therapeutics Inc
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Ciusss de L'Est de l'Île de Montréal
University of Michigan Rogel Cancer Center
OHSU Knight Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Singapore General Hospital
Polyphor Ltd.
Singapore General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Erlangen-Nürnberg Medical School
National Cancer Institute (NCI)
Asan Medical Center
Washington University School of Medicine
Baylor College of Medicine
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Chroma Therapeutics
Fred Hutchinson Cancer Center